Certificate of Analysis (CoA) and Traceability Systems: A Comprehensive Guide for Pharmaceutical Packaging
Introduction: The Twin Pillars of Pharmaceutical Quality Assurance
In the pharmaceutical industry, patient safety depends on a complex ecosystem of quality documentation and supply chain visibility. Two elements stand at the center of this ecosystem: the Certificate of Analysis (CoA) and traceability systems. Together, they form the foundation upon which regulatory compliance, product integrity, and patient trust are built.
A Certificate of Analysis is an official quality document issued by a supplier or an accredited laboratory, containing test results for a specific production batch. It demonstrates that the product meets agreed specifications and applicable pharmacopeial standards. In the regulatory context, a CoA is not merely a supplementary document—it is a mandatory requirement in batch release records. FDA (21 CFR 211.84), EMA, and other regulatory bodies require every batch of primary packaging material to be inspected and documented before production use.
Traceability systems, on the other hand, provide the infrastructure to track pharmaceutical products and packaging components throughout the supply chain. From unit-level serialization under the Drug Supply Chain Security Act (DSCSA) to full batch traceability required by ISO 15378, these systems ensure that every component can be traced from origin to administration.
At Vialab Pharmaceutical Packaging Co., Ltd., we understand that quality documentation and traceability are inseparable. Our comprehensive product portfolio—including injection pens, glass vials, sterile vials, and aluminum caps—is manufactured under strict quality control systems compliant with ISO and GMP standards. Every batch we produce is accompanied by a complete Certificate of Analysis and is fully traceable through our quality management system. This article provides a comprehensive overview of CoA requirements and traceability systems in pharmaceutical packaging, covering regulatory frameworks, best practices, and emerging trends.
Part I: Certificate of Analysis (CoA) — The Document of Record
Regulatory Framework for CoA
The regulatory requirements for Certificates of Analysis are established across multiple global standards. In the United States, 21 CFR Part 211 sets forth the GMP requirements for pharmaceutical packaging. Specifically, 21 CFR 211.84 requires that each lot of components, drug product containers, and closures be withheld from use until sampled, tested, or examined, and released by the quality control unit.
Under 21 CFR 211.84(d)(2), a manufacturer may accept a supplier’s Certificate of Analysis in lieu of full testing, provided that at least one specific identity test is conducted on each component lot, and the manufacturer establishes the reliability of the supplier’s analyses through appropriate validation at appropriate intervals. This provision places a significant responsibility on pharmaceutical manufacturers to qualify their suppliers and verify the reliability of CoA data.
The USP provides additional guidance through General Chapter <1080>, “Bulk Pharmaceutical Excipients—Certificate of Analysis,” which serves as a guide for the preparation and appropriate use of a CoA for pharmaceutical excipients. The chapter aims to standardize the content and suggest a format for CoAs, and to clearly define the roles and responsibilities for the manufacturer and distributor.
For primary packaging materials, ISO 15378:2017 is the internationally recognized GMP standard specifically designed for primary packaging materials for medicinal products. Built on ISO 9001 principles, it integrates pharmaceutical-grade requirements such as risk-based process control, contamination management, and traceability. The standard includes criteria concerning manufacturing batches and their traceability, control of environmental conditions, validation of critical processes, and risk management.
Essential Components of a Pharmaceutical CoA
A comprehensive pharmaceutical packaging CoA must include several critical sections:
Material Identification: This section identifies the product being tested, including glass type (Type I/II/III), color, product name and item code, and nominal dimensions.
Batch Information: Traceability data linking the CoA to a specific production batch, including batch/lot number, production date, test date, and batch quantity.
Test Results: The core section containing actual test values, including test method, result values, acceptance criteria, and pass/fail status. For glass packaging, key tests include hydrolytic resistance (HGA and HGB), thermal shock, dimensional measurements, and extractables.
Acceptance Criteria and Approval: Each test parameter must have clear acceptance criteria and a conformance statement, signed by an authorized person with name, title, and date. The issuing laboratory should be identified, ideally with ISO/IEC 17025 accreditation.
Certificate of Compliance (CoC): A related document declaring that the product complies with GMP, pharmacopeia, and regulatory expectations.
The Danger of Overreliance on CoAs
Regulatory authorities have increasingly scrutinized companies that rely too heavily on supplier CoAs without independent verification. As noted in a 2025 industry report, some companies are overly reliant on their suppliers’ Certificates of Analysis and are failing to confirm the appropriateness of testing—a practice that has led to significant FDA Form 483 observations.
A striking example came in March 2025, when the FDA issued a Warning Letter to a Chinese drug manufacturing facility. The agency identified serious CGMP violations, including:
- Failure to test identity and quality of incoming raw materials: The firm relied solely on suppliers’ CoAs without performing required identity tests
- Lack of supplier qualification: No formal vendor qualification program existed
- Data integrity violations: Laboratory records lacked complete and original data to support the analyses performed
The FDA concluded that the firm “used results from your suppliers’ certificates of analysis (COAs) without establishing the reliability of your suppliers’ analyses through appropriate validation and without conducting at least one specific identity test on each incoming lot of components”. The firm was placed on Import Alert 66-40 (“Detention Without Physical Examination”).
In another inspection, a distributor was cited under 21 CFR 211.165(a) for failing to justify the appropriateness of its supplier’s testing of the finished product before release. The distributor relied entirely on a CoA from its Contract Manufacturing Organization without verifying the adequacy of the tests.
These enforcement actions underscore a critical lesson: CoAs are only as reliable as the systems and controls behind them. GMP regulations explicitly require firms to independently verify the adequacy and appropriateness of tests rather than solely depending on supplier-provided information.
Best Practices for CoA Management
To mitigate risks and ensure regulatory compliance, pharmaceutical manufacturers should adopt the following best practices:
1. Perform Independent Testing: Conduct identity, potency, and purity testing for all incoming materials and finished products, regardless of CoA data. At minimum, a specific identity test must be performed on each incoming lot.
2. Establish Robust Supplier Qualification Programs: Conduct regular audits, risk assessments, and performance reviews to ensure suppliers meet GMP standards. Quality agreements should cover responsibilities and notification clauses.
3. Document Quality Control Processes: Maintain comprehensive records of all testing and verification activities to demonstrate compliance during inspections.
4. Invest in Staff Training: Educate quality teams on regulatory expectations and the risks of overreliance on CoAs.
5. Periodically Re-evaluate Suppliers: Based on risk and performance, suppliers should be periodically re-evaluated.
Part II: Traceability Systems — From Batch to Unit
The Regulatory Landscape for Traceability
Traceability in pharmaceutical packaging operates at two levels: batch-level traceability required by GMP standards and unit-level serialization mandated by drug supply chain security regulations.
ISO 15378: Batch-Level Traceability
ISO 15378 requires full batch traceability, from incoming raw materials to final shipment. The standard specifies requirements for a quality management system when an organization is involved in the design, manufacture, and supply of primary packaging materials for medicinal products. Key traceability requirements include:
- Documented control of manufacturing batches and their traceability
- Control of environmental conditions (cleanliness and hygiene)
- Validation of critical processes
- Risk management methodologies based on ICH Q9
ISO 15378 certification is not static; it is actively maintained through annual surveillance audits by an accredited third-party body. These audits include reviews of preventive actions, supplier control, equipment maintenance, and GMP awareness across functions.
DSCSA: Unit-Level Serialization
The Drug Supply Chain Security Act (DSCSA), signed into law in 2013, represents a paradigm shift in pharmaceutical traceability. As of November 2026, every bottle of medicine moving through the U.S. supply chain must be tracked electronically at the unit level. This isn’t lot-level tracking anymore—it’s individual serialization.
A core mandate of the DSCSA is unit-level serialization, which requires that every prescription drug package bear a unique product identifier in a two-dimensional barcode. This product identifier must include:
- National Drug Code (NDC)
- Serial number
- Lot number
- Expiration date
The DSCSA requires interoperable electronic systems to trace prescription drugs at the package level. As of May 27, 2025, the FDA officially began enforcing the law’s final requirements. Key requirements include:
- EPCIS adoption as the data standard for event-based traceability
- Interoperability across systems so manufacturers, distributors, and dispensers can exchange and interpret serialized data consistently
- Verification of product identifiers and investigation of suspect or illegitimate products
- Record retention of traceability and transaction records for at least six years
The Convergence of CoA and Traceability
The Certificate of Analysis and traceability systems are not separate quality functions—they are deeply interconnected. A CoA is batch-specific and must match the current lot of material being used. The batch/lot number on the CoA serves as the critical link to the traceability system, enabling:
- Recall readiness: If a quality issue is identified, the CoA and traceability data together enable rapid identification and isolation of affected batches
- Investigation support: When deviations occur, traceability data provides the context needed to understand the scope and root cause
- Regulatory inspection readiness: Auditors routinely inspect documentation related to supplier qualification, material traceability, and change management
Emerging Technologies in Traceability
The future of pharmaceutical traceability is moving toward permanent, immutable digital identity embedded directly into packaging. Recent trials have demonstrated how permanently embedded, tamper-resistant digital microtransponders can maintain a continuous and auditable connection between a drug’s physical form and its digital record. These technologies enable a true Chain-of-Identity and Chain-of-Custody from origin to administration.
Traditional adhesive labeling approaches such as barcodes and RFIDs are vulnerable to damage, theft, and copying. Additionally, traditional labeling methods do not survive the extreme low temperatures required for cryogenic storage and shipping of thermolabile medications. Emerging technologies address these limitations by providing:
- Unit-level digital identity that is unique, unclonable, and unalterable
- Secure linkage between physical drug units and their digital transaction records
- Audit-ready traceability to support regulatory compliance requirements
Part III: Vialab’s Commitment to Quality Documentation and Traceability
At Vialab Pharmaceutical Packaging Co., Ltd., we recognize that Certificates of Analysis and traceability systems are foundational to patient safety. Our comprehensive product portfolio is designed and manufactured to support our customers’ quality documentation and traceability requirements:
Injection Pens (Disposable & Reusable): Each batch is accompanied by a complete CoA documenting critical quality attributes, with full traceability from raw materials to finished product.
Glass Vials & Tubes (Parenteral Grade, Precise Dimensions): Our parenteral-grade glass vials are manufactured to exacting specifications with comprehensive CoA documentation including hydrolytic resistance, dimensional measurements, and extractables testing.
Sterile Vials (Ready-To-Use, Wash & Sterilized): Pre-washed and sterilized vials are accompanied by complete documentation of cleaning validation, sterilization processes, and final release testing.
Aluminum & Aluminum-Plastic Caps (Tamper-Evident, Various Sizes): Each batch is traceable from raw material sourcing to final shipment, with CoA documentation of all critical quality attributes.
Customized Packaging Solutions: Tailored to meet specific customer requirements, including custom CoA formats and traceability data exchange protocols.
Our advanced production lines and cleanroom facilities ensure consistent quality, integrity, and compliance for global healthcare partners. We maintain strict quality control systems compliant with ISO and GMP standards, understanding that quality documentation and traceability are not one-time requirements but continuous lifecycle commitments.
Conclusion
Certificate of Analysis and traceability systems are the twin pillars of pharmaceutical quality assurance. The CoA provides the documented evidence that a batch meets its specifications, while traceability systems ensure that every component can be tracked throughout the supply chain.
Key takeaways for pharmaceutical manufacturers and packaging suppliers:
- CoAs are mandatory, not optional: FDA (21 CFR 211.84), EMA, and other regulators require CoAs for every batch of primary packaging material
- Independent verification is essential: Do not rely solely on supplier CoAs—perform at least identity testing and establish supplier reliability
- Traceability is a regulatory imperative: DSCSA requires unit-level serialization with electronic data exchange
- ISO 15378 provides the framework: For primary packaging manufacturers, ISO 15378 integrates GMP requirements with full batch traceability
- Documentation and traceability are interconnected: The batch/lot number on the CoA is the critical link to the traceability system
As regulatory requirements continue to evolve—with DSCSA enforcement now in full effect and ISO standards undergoing continuous improvement—lifecycle-driven quality documentation and traceability are no longer optional. They are foundational to compliant, resilient manufacturing and, ultimately, to patient safety.
At Vialab Pharmaceutical Packaging Co., Ltd., we remain committed to delivering packaging solutions that meet the highest standards of quality documentation and traceability—because when it comes to patient safety, there is no room for compromise.